A practical reference on NAD+ salvage: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-16 and is reviewed periodically as new material appears.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. As an intermediate in the NAD+ salvage pathway, NMN is converted to nicotinamide adenine dinucleotide, a coenzyme central to cellular redox reactions. NAD+ also serves as a substrate for enzymes involved in DNA repair, stress responses, and metabolic regulation. The compound is therefore part of normal cellular biochemistry rather than an exclusively synthetic molecule.
Two enzymatic steps define the canonical route from nicotinamide to NAD+. Nicotinamide phosphoribosyltransferase, known as NAMPT, produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN adenylyltransferases, or NMNAT enzymes, then couple NMN with ATP to form NAD+. Whether intact NMN crosses cell membranes efficiently remains an active area of investigation; some studies propose direct transport, while others emphasize extracellular dephosphorylation to nicotinamide riboside followed by uptake. The relative contribution of each route likely depends on cell type, tissue, and experimental conditions.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C11H15N2O8P | Canonical beta anomer; charge state depends on pH. |
| Molar mass | 334.22 g/mol | Calculated for the neutral formula. |
| CAS Registry Number | 1094-61-7 | Common identifier for beta-nicotinamide mononucleotide. |
| Appearance | White to off-white powder or crystals | Varies with purity, hydration, and polymorphism. |
| Solubility | Freely soluble in water; low solubility in nonpolar solvents | Reported values depend on salt form and temperature. |
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
NMN occurs in many living systems, including bacteria, yeast, plants, and mammals. Dietary sources are present in foods such as edamame, avocado, broccoli, and various meats, but amounts vary widely and are generally lower than those used in research settings. Laboratory production often relies on enzymatic synthesis or chemical phosphorylation of nicotinamide riboside, and commercial material is typically supplied as a white to off-white powder. Because NMN is hygroscopic and sensitive to heat, moisture, and pH extremes, its handling requires care to preserve identity and purity. Aqueous preparation should be done with attention to pH and temperature to limit hydrolysis.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure consists of a nicotinamide ring linked to ribose phosphate, and the compound serves as an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+. In this pathway, nicotinamide phosphoribosyltransferase converts nicotinamide and phosphoribosyl pyrophosphate into NMN, after which NMN adenylyltransferase attaches an adenylate group to produce NAD+. Because NAD+ participates in redox reactions and signaling, NMN occupies a central position in cellular metabolism. The molecule is distinct from nicotinamide riboside, though the two are related in NAD+ precursor research.
Beyond its intracellular synthesis, NMN can be taken up from the extracellular environment, although the routes are still debated. Some evidence points to direct transport into cells through specific transporters, while other work suggests dephosphorylation to nicotinamide riboside followed by cellular uptake. Once inside, NMN can be converted to NAD+ by NMN adenylyltransferases; the relative contribution of these routes may differ by tissue, species, and experimental conditions. Researchers continue to investigate which mechanisms dominate in intact organisms and how they affect measured NAD+ levels. Direct measurement in tissues remains technically challenging because NMN can be rapidly metabolized during sample collection.
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
==== Development of oral antivirals ==== In November 2021, Pfizer launched a new COVID-19 oral antivirus treatment known as Paxlovid. In January 2022, the Pfizer CEO Albert Bourla confirmed that the trial results of a fourth dose were pending until March 2022. He said that the firm was setting up a collaboration to develop an anti-COVID pill treatment along with a French company, Novasep. He also said the COVID vaccine was "safe and efficient" for children. In May 2022, reports emerged of patients experiencing "rebound" symptoms after completing a five-day course of Paxlovid. The FDA responded by announcing they had performed additional analyses of the drug's clinical trial data, and decided against changing its recommendations. U.S. President Joe Biden and Dr. Anthony Fauci were both reported to experience this rebound syndrome in the months that followed, while continuing to recommend the drug for those who may benefit from it.
== Selection and training == From early 1978 to 1980, support, training, and selection consisted of 3 phases, culminating latterly in 6 months/24 weeks training, with the first phase lasting as long as 11 weeks (the RLI's first phase was 6 weeks). Emphasis in selection depended on extreme physical fitness and aggression (running at an excess of 120 kilometres per week), mental strength in decision making and problem solving under extreme duress. The selection course consisted of a junior leader assessment in all areas concerning leadership. All Counter Operations Insurgency (COIN) battle drills were held in battle camps at Concession and Shamva. The pass rate among recruits amounted to only 30%. On passing out, recruits were deployed to one of 13 and latterly 14 troops (Troop company strength being 120 men; Mantle Mounted and November Troop being new additions in 1981). The Support Unit supported the Police in rural problem areas (latterly dissidents), as well as in urban emergencies. In November 1980, during the Entumbani I uprising, two sections of 60 men each from 5 Support Unit Troops (Mantle Echo, Mantle Charlie, Mantle Juliet, Mantle Hotel, Mantle Lima, 300 men in all), travelled from all over Zimbabwe to reach Bulawayo in 11 hours. Due to the Support Unit Troops being independent with their own vehicles, stores, ammunition, medical supplies, tents etc., they could deploy anywhere at a moment's notice all over Zimbabwe.
=== Natural environment === Emley Moor, site of the tallest self-supporting structure in the UK (a TV mast) Harewood Estate – Leeds Country Way public footpath runs through the estate, landscaped gardens and home to Red Kites amongst many other birds Ilkley Moor, part of Rombalds Moor New Swillington Ings Nature Reserve Otley Chevin – extensive wooded parkland on high ground with extensive views North over Wharfedale and South as far as the Peak District RSPB Fairburn Ings and St Aidan's – wetland centres for birds Seckar Woods LNR, a Local Nature Reserve Walton Hall, West Yorkshire, home of naturalist Charles Waterton and the world's first nature reserve
=== Fosfomycin === Several antimicrobial drugs have been tested for the effective treatment of CRE. Fosfomycin is an antimicrobial agent that acts to inhibit UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) which catalyzes one of the early steps of bacterial cell wall synthesis, and is effective against gram-negative and -positive aerobic bacteria, such as CRE. A meta-analysis of 17 studies investigating the clinical effectiveness of fosfomycin in four multidrug-resistant strains of Enterobacteriaceae found 11 which reported that over 90% of bacterial isolates were susceptible to fosfomycin. The elevated level of antimicrobial activity by fosfomycin can be attributed to the fact that resistance to this antibiotic in Enterobacteriaceae is chromosomally encoded and not plasmid-mediated. This causes a decreased capacity for survival in the bacteria. Bacteria that are naturally resistant to fosfomycin are less robust and less pathogenic.
Sources: en.wikipedia.org
Afterwards, he reinforced this vision by implementing measures such as requiring ministers to declare their assets, limiting land applications to one piece per leader, discouraging conflicts of interest with public-listed companies, and advising against ostentation and visits to nightclubs. Mahathir further emphasized this vision by launching the "Leadership-by-Example" campaign in 1983 at Stadium Tun Razak, Kuala Lumpur, encouraging leaders and civil servants to uphold integrity, professionalism, and ethical behaviour in order to inspire public trust and ensure that national objectives were achieved through exemplary conduct. In 1983, Mahathir undertook one of the first challenges he had with Malaysia's royalty. The position of Yang di-Pertuan Agong, the Malaysian head of state, was due to rotate into either the elderly Idris Shah II of Perak or the controversial Iskandar of Johor, who had only a few years earlier been convicted of manslaughter. Mahathir had grave reservations about the two Sultans, who were both activist rulers of their own states. Mahathir tried to pre-emptively limit the power that the new Agong could wield over his government. He introduced to parliament amendments to the Constitution to deem the Agong to assent to any bill that had not been assented within 15 days of passage by Parliament. The proposal removed the power to declare a state of emergency from the Agong and placed it with the prime minister.
== Treatment == The primary treatment for urethral diverticulum is surgical. In women, the surgery is conducted transvaginally, usually when there is no acute inflammation to better aid dissection of the delicate tissues.
=== Valve Corporation v. Vivendi Universal Games === Between 2002 and 2005, Valve was involved in a complex legal dispute with its publisher, Vivendi Universal Games (under Vivendi's brand Sierra Entertainment). Valve had entered into a publishing agreement with Sierra to release Half-Life and subsequent games in 1997, with the contract giving Sierra some intellectual property (IP) rights to Valve's games. After Valve began development of Half-Life 2, it agreed a new contract with Sierra in 2001, removing these rights from Sierra and giving Valve some rights for digital distribution. Internally, Valve started work on Steam as a means to digitally distribute these games, and first revealed this project at the March 2002 Game Developers Conference. By August 2002, Valve had found that Sierra was distributing copies of their games to Internet cafes against the terms of their contracts and filed a lawsuit against Sierra and Vivendi. In addition to claims of copyright infringement, Valve asserted that Sierra breached contract by withholding royalties and delaying the release of Counter-Strike: Condition Zero until after the holiday season. Vivendi and Sierra countersued, stating that Valve had misrepresented their position in the revised 2001 contract since they had been working on Steam at that point as a means to circumvent the publishing agreement. Vivendi sought intellectual property rights to Half-Life and a ruling preventing Valve from using Steam to distribute Half-Life 2. The countersuits, if successful, likely would have bankrupted Valve, according to COO Scott Lynch.
=== Whole genome sequencing (WGS) === Whole genome sequencing and genomics applications can be used for large-scale alignment and comparative analysis with both bacteria and fungi. WGS can be used to diagnose, identify, or characterize an organism down to the individual base pairs by sequencing the entire genome. WGS can also be used to compare the genomes or average nucleotide identity (ANI) of the shared genes between two strains and can be a robust way to compare genetic relatedness and if often used for investigating organisms involved in foodborne illness and other outbreaks.
==== Genetic defects ==== Genetically confirmed diagnoses of diseases affecting vitamin B6 metabolism (ALDH7A1 deficiency, pyridoxine-5'-phosphate oxidase deficiency, PLP binding protein deficiency, hyperprolinaemia type II and hypophosphatasia) can trigger vitamin B6 deficiency-dependent epileptic seizures in infants. These are responsive to pyridoxal 5'-phosphate therapy.
Sources: en.wikipedia.org
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ metabolism. It occurs naturally in cells and can also be produced synthetically for research or commercial use. Its name reflects its composition: nicotinamide, ribose, and a phosphate group.
NMN is a direct precursor in the NAD+ salvage pathway. NMNAT enzymes convert NMN and ATP into NAD+, a coenzyme used in many cellular reactions. This relationship makes NMN a focus of studies on NAD+ metabolism.
Small amounts of NMN have been reported in some plant foods, but measured levels vary and are not consistently quantified. Dietary contribution is generally considered minor compared with endogenous production. Food-matrix effects make accurate analysis difficult.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It occurs naturally in cells and is also produced commercially as a supplement ingredient.